Clinical trials: Losartan
Hypertension
Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Blood pressure (BP) is believed to be a major determinant of vascular disease, and BP lowering is the most important goal in hypertension treatment.
- Trial name
- NCT01964079
- Testing
- Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Wonju Severance Christian Hospital
Healthy
Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of losartan 100 mg tablets (test) versus Cozaar® (reference), administered as 1 * 100 mg tablet under fasting conditions.
- Trial name
- NCT01124162
- Testing
- Losartan, Cozaar®
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart.
- Trial name
- NCT00338260
- Testing
- MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years
- Volunteers
- 496 people
- Sponsor
- Organon and Co
Hypertrophic Cardiomyopathy
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle…
- Trial name
- NCT01150461
- Testing
- losartan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Cardiovascular Diseases, Hypertension
Secondhand Tobacco Smoke and Cardiovascular Disease
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic…
- Trial name
- NCT04715568
- Testing
- Losartan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
HIV-1 Infection
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
This is a open controlled trial in which 48 HIV-1 patients successfully treated with EFV/FTC/TDF will be randomized to one of 4 groups in equal proportion between arms (1:1).
- Trial name
- NCT01529749
- Testing
- EFV/FTC/TDF + Losartan, EFV/FTC/TDF, FTC/TDF + MK-0518
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Felipe Garcia
Hypertension
Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions
This is a three-period, three sequence, reference replicated, cross-over study to determine the bioequivalence of two amlodipine and losartan FDC tablet formulations FDC5/50 and FDC5/100 (GSK2944406; 5 mg amlodipine and 50 mg and…
- Trial name
- NCT01797926
- Testing
- Reference Treatment: 5 mg amlodipine + 50 mg losartan, Reference Treatment:5 mg amlodipine + 100 mg losartan, FDC 5/50 amlodipine/ losartan
- Where
- South Africa
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Coronary Arterial Disease
Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary…
- Conditions
- Hypertension, Coronary Arterial Disease, Percutaneous Coronary Intervention
- Trial name
- EDAM (NCT07683585)
- Testing
- Losartan + Hydrochlorothiazide, Amlodipine + Azilsartan
- Where
- Russia
- Volunteers
- 207 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Proteinuria
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage.
- Trial name
- NCT06491940
- Testing
- Losartan, Losartan + Hydrochlorothiazide
- Where
- Pakistan
- Volunteers
- 234 people
- Sponsor
- RESnTEC, Institute of Research
Healthy
The Pharmacokinetic Interaction Between Amlodipine and Losartan
This clinical trial aims to assess the pharmacokinetic interaction between amlodipine and losartan in healthy male subjects.
- Trial name
- NCT03912285
- Testing
- Amlodipine10mg, Losartan potassium 100mg, Amlodipine plus Losartan
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Hypertension
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers
The purpose of this study is to evaluate the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine and losartan in healthy volunteers.
- Trial name
- NCT01648231
- Testing
- Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state, Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state, Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
- Where
- Australia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nephropathy, Sickle Cell Anemia
Losartan to Reverse Sickle Nephropathy
Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease.
- Trial name
- NCT01479439
- Testing
- Losartan
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.
- Trial name
- NCT04830449
- Testing
- HCP1904-2, RLD2001-2
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension(HTN)
Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
- Trial name
- NCT02387554
- Testing
- HGP0904, HGP0608, HGP1405
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy
Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and…
- Conditions
- Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy, Severe Aortic Stenosis
- Trial name
- ARBITAR (NCT07735130)
- Testing
- Angiotensin Receptor Blocker (ARB)
- Where
- South Korea
- Volunteers
- 632 people
- Sponsor
- Seoul National University Hospital
Losartan Adverse Reaction, Uropathy
The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney
Previous experimental studies concluded that angiotensin receptor blockers can ameliorate the harmful inflammatory and histological changes after relief of obstruction.
- Conditions
- Losartan Adverse Reaction, Uropathy, Uropathy Obstructive
- Trial name
- NCT04278495
- Testing
- Cozaar (Losartan Potassium 25mg)
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Mansoura University
Hypertension, Dyslipidemia
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
This study was to evaluate the therapeutic effect and safety of amosartan Q tablet administration in adult patients with hypertension and dyslipidemia.
- Trial name
- NCT05450575
- Testing
- Amosartan Q tablet
- Where
- South Korea
- Volunteers
- 5,400 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Stage D Heart Failure
Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device…
- Trial name
- SEAL-IT (NCT04191681)
- Testing
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
Hypertension
Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan with Amosartan, which was available commercially after single oral dose in healthy male subjects.
- Trial name
- NCT02504606
- Testing
- Besylsartan, Amosartan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Kidney Disease
Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers
The purpose of this study is to find out how chemicals in the blood of patients with chronic kidney disease affect how medications are removed from the body.
- Trial name
- CKD (NCT01087749)
- Testing
- Propranolol, Losartan, Eprosartan
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco